A5100364976- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- PI3K/AKT/mTOR signaling in cancer
- Cancer Genomics and Diagnostics
- Molecular Biology Techniques and Applications
- HER2/EGFR in Cancer Research
- Metastasis and carcinoma case studies
- Colorectal and Anal Carcinomas
- Berberine and alkaloids research
- Cancer therapeutics and mechanisms
- Vascular Anomalies and Treatments
- Photodynamic Therapy Research Studies
- Musculoskeletal pain and rehabilitation
- Vascular anomalies and interventions
- Gastroesophageal reflux and treatments
- Bladder and Urothelial Cancer Treatments
- Glutathione Transferases and Polymorphisms
- RNA modifications and cancer
- Cutaneous Melanoma Detection and Management
- Ocular Oncology and Treatments
- Cytokine Signaling Pathways and Interactions
- Pain Management and Placebo Effect
- Urinary and Genital Oncology Studies
Weatherford College
2024
Tsinghua University
2021-2024
Neijiang Normal University
2020-2024
Beijing Proteome Research Center
2024
Hebei Medical University
2022
Fourth Hospital of Hebei Medical University
2022
State Key Laboratory of Genetic Engineering
2022
Hefei First People's Hospital
2022
First Affiliated Hospital of Chengdu Medical College
2022
Chongqing Medical University
2020-2022
A major question regarding the sensitivity of solid tumors to targeted kinase inhibitors is why some respond and others do not. The observation that many express EGF receptor (EGFR), yet only a small subset with EGFR-activating mutations clinically EGFR (EGFRIs), suggests responsive uniquely depend on signaling for their survival. nature this dependence not understood. Here, we investigate by comparing non-small-cell lung cancer cell lines driven genomic amplifications using global proteomic...
Abstract Metabolic reprogramming evolves during cancer initiation and progression. However, thorough understanding of metabolic evolution from preneoplasia to lung adenocarcinoma (LUAD) is still limited. Here, we perform large-scale targeted metabolomics on resected lesions plasma obtained invasive LUAD its precursors, decipher the trajectories atypical adenomatous hyperplasia (AAH) in situ (AIS), minimally (MIA) (IAC), revealing that perturbed pathways emerge early premalignant lesions....
Six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a relatively newly identified gene target from prostate cancer, breast and gastric cancer. However, functions STEAP1 in lung adenocarcinoma (LUAD) are still unknown. In the present study, we explored molecular cellular mechanisms LUAD. Western blot Q-PCR were conducted to detect protein mRNA expressions respectively. The cell proliferation was tested by CCK8 assay. effects on metastasis epithelial-mesenchymal transition (EMT)...
Abstract The ultrafast‐laser‐matter interactions enable “top‐down” laser surface structuring, especially for materials difficult to process, with “bottom‐up” self‐organizing features. subwavelength scenarios of laser‐induced structuring are improved in defects and long‐range order by applying positive/negative feedbacks. It is still hardly reported supra‐wavelength more associated complicated thermo/hydro‐dynamics. For the first time knowledge, near‐field‐regulated ultrafast‐laser...
This study aims to screen the potential targets of tetrandrine (Tet) against pulmonary fibrosis (PF) based on network pharmacological analysis, molecular docking and experimental verification.The pharmacology methods were employed predict targets, construct Tet-PF-intersection target-pathway networks, candidate targets. The was performed using AutoDockTools1.5.6. TGF-β1-induced human lung adenocarcinoma A549 cells used as an in vitro verification model, taking dexamethasone (Dex) positive...
Abstract Phosphoinositide-3 kinase alpha-specific inhibitors (PI3Kαi) displayed promising potential for the treatment of esophageal squamous cell carcinoma (ESCC) with frequent activation in PI3K signaling. However, acquired resistance is likely to develop and limit efficacy PI3Kαi like other targeted therapies. To identify genomic adaptation PI3Kαi, we applied whole-genome sequencing detected gene mutation amplification four lines ESCC cells established adapted a novel CYH33. Particularly,...
ZNRF3 and RNF43 are closely related transmembrane E3 ubiquitin ligases with significant roles in development cancer. Conventionally, their biological functions have been associated regulating WNT signaling receptor ubiquitination degradation. However, our proteogenomic studies revealed EGFR as the most negatively correlated protein ZNRF3/RNF43 mRNA levels multiple human cancers. Through biochemical investigations, we demonstrate that interact via extracellular domains, leading to subsequent...
ZNRF3 and RNF43 are closely related transmembrane E3 ubiquitin ligases with significant roles in development cancer. Conventionally, their biological functions have been associated regulating WNT signaling receptor ubiquitination degradation. However, our proteogenomic studies revealed EGFR as the most negatively correlated protein ZNRF3/RNF43 mRNA levels multiple human cancers. Through biochemical investigations, we demonstrate that interact via extracellular domains, leading to subsequent...
To further identify the association between lymph node micrometastasis (LNM) and long-term survival among pN0 esophageal cancer patients receiving surgery.
Abstract Targeted therapy offers a new option for patients with advanced lung adenocarcinoma patients. However, long‐term targeted may transform into small cell cancer (SCLC). Herein, we report 48‐year‐old female patient pulmonary and ureteral metastasis which transformed from to SCLC after surgical therapies. She was diagnosed invasive undergoing the surgery. Two years later recurrence occurred she given gefitinib osimertinib. therapy, right mass (4.9 × 3.7 3.8 cm) pathologically found,...
Background:GPC5 rs2352028 is associated with the risk of lung cancer, but its relationship cancer prognosis unclear. Materials & methods: The authors collected blood samples from 888 patients and used a Cox proportional hazards model to analyze association between GPC5 polymorphism rs2352028. Results:GPC5 C > T was better prognosis. Patients CT genotype had longer overall survival than those CC genotype. Additionally, older early-stage + TT lower death Conclusion:GPC5 may play protective...
Objective To explore the clinical effect of Weifuchun tablet combined with chemotherapy on patients advanced non-small cell lung cancer (NSCLC).Methods Sixty-eight NSCLC was randomly divided into control group (n =34) treated cisplatin + gemcitabine and treatment (1.436g × 2/d) gemcitabine.After two cycles,the in both groups were evaluated.Results The efficacy 52.94％ (18/34),which 41.18％ (14/34),there no statistically significant difference between groups(x2 =0.94,P ＞ 0.05).The quality life...
Objective To investigate the clinical effect of induction chemotherapy plus concurrent radiochemotherapy in treatment locally advanced non-small cell lung cancer (NSCLC) through a meta-analysis. Methods CBM, CNKI, Cochrane Library, PubMed, and EMbase were searched for articles on comparison between patients with NSCLC. According to inclusion exclusion criteria, data short-term outcome survival collected. A Meta-analysis was performed evaluate followed by...
Objective To retrospectively evaluate the efficacy in non-small cell lung cancer (NSCLC) patients with brain metastases treated erlotinib ± whole radiotherapy, and observe adverse events. Methods From March 2012 to January 2015, 56 NSCLC received oral erlotinib, at a dose of 150mg per day till disease progression or intolerable events were developed, including 42 cases who had radiotherapy.The objective response rate (ORR) control (DCR) observed between groups, progression-free...
Abstract Non-small cell lung cancer (NSCLC) is the most common form of cancer, afflicting nearly 200,000 people in United States each year. Abnormal ALK found about 5% NSCLC cases, meaning more than 5,000 new patients could benefit from tyrosine kinase inhibitor (TKI) crizotinib. However, not all such treatment, with clinical response to crizotinib differing among who harbor same molecular abnormality. Similarly, fusion proteins have shown varying sensitivity HSP90 geldanamycin preclinical...